Fine control of drug delivery for cochlear implant applications

Homsy, Alexandra; Laux, Edith; Brossard, J.; Whitlow, Harry J.; Roccio, Marta; Hahnewald, Stefan; Senn, Pascal; Mistrík, Pavel; Hessler, Roland; Melchionna, Teresa; Frick, Claudia; Löwenheim, Hubert; Müller, Marcus; Wank, Ute; Wiesmüller, Karl‐Heinz; Keppner, H.

doi:10.3109/21695717.2015.1048082

Cited by 11 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optimization of the electrode nerve interface could be achieved by introducing drug substances into the cochlea which could cause the growth of neurites to the electrode [21,22].…”

Section: Researches On Optimizing the Performance Of Current Implantsmentioning

confidence: 99%

Cochlear Implant Strategies and Biomaterials from Past to Future

Martu¹,

Cozma²,

Martu³

et al. 2017

Mat.Plast.

View full text Add to dashboard Cite

The cochlear implant (C.I.) is a neurobionic prosthesis, being one of the greatest achievements of auditory neuroscience. Although C.I. represents the gold standard in the treatment of deafness in both the child and the adult, some problems like perception of speech in noise (atmosphere, environment), perception of music, binaural hearing remain, aspect to which improvements are expected. The article (this review) revises the road from the first attempts to cochlear implantation to today�s modern and reliable cochlear implant. Continuous improvement of existing technology both in terms of biomaterials used and in terms of speech processing and simultaneous stimulation strategies, promise with certainty the introduction of C.I. with superior performance. A look in the future is through new ideas and techniques, which await the transition from the experimental to the clinical stage in the emergence of a new generation of implants.

show abstract

“…Optimization of the electrode nerve interface could be achieved by introducing drug substances into the cochlea which could cause the growth of neurites to the electrode [21,22].…”

Section: Researches On Optimizing the Performance Of Current Implantsmentioning

confidence: 99%

Cochlear Implant Strategies and Biomaterials from Past to Future

Martu¹,

Cozma²,

Martu³

et al. 2017

Mat.Plast.

View full text Add to dashboard Cite

show abstract

“…The CI-based platforms were created by coating a silicone substrate with a Parylene fi lm, which confers low water permeability and biocompatibility. [ 25 ] The Parylene fi lm had an average thickness of 1.2 µm and was created at the HES-SO University of Applied Sciences (Switzerland). Henceforth, "CI" will refer to the Parylene-silicone CI-based platform and "coating" will refer to the NPs.…”

Section: Methodsmentioning

confidence: 99%

“…There was a 20% reduction in alamarBlue signal from HF cultured with uncoated CI fragments relative to the HF cultured in an empty microplate well (without any fragment in place). This could be explained by some adverse effects on cell viability from the Parylene layer (generally considered inert and biocompatible) [ 25 ] and/or a mechanical effect of the free-fl oating implant fragments. Alternatively, as the readings were performed with the fragment inside the wells, this phenomenon could also be an effect of shadowing.…”

Section: Biocompatibilitymentioning

confidence: 99%

“…[ 25 ] Silicone used alone as a layer on the implant provides biocompatibility but allows water penetration; the latter may affect the electrical properties of the device such as the impedance. Adding a Parylene layer on the CI, although not a typical procedure, blocks water permeability into the device and can improve its functionality.…”

Section: Structure and Morphology Of The Coated Surfacesmentioning

confidence: 99%

“…Adding a Parylene layer on the CI, although not a typical procedure, blocks water permeability into the device and can improve its functionality. [ 25 ] Henceforth, "CI" will refer to the Parylene-silicone CI-based platform, and "coating" will refer to the NPs. The sonochemical deposition was carried out by ultrasound-assisted irradiation of the precursor solution in the presence of the solid surface; this coating procedure is called in situ.…”

Section: Structure and Morphology Of The Coated Surfacesmentioning

confidence: 99%

See 2 more Smart Citations

Two are Better than One: Combining ZnO and MgF₂ Nanoparticles Reduces Streptococcus pneumoniae and Staphylococcus aureus Biofilm Formation on Cochlear Implants

Natan

Edin

Perkas

et al. 2016

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Streptococcus pneumoniae (S. pneumoniae) and Staphylococcus aureus (S.aureus) are considered the most common colonizers of cochlear implants (CI), which have prompted the search for new ways to inhibit their growth and biofilm development. In the current study, CI‐based platforms are prepared and sonochemically coated with ZnO or MgF2 nanoparticles (NPs), two agents previously shown to possess antibacterial properties. Additionally, a method is developed for coating both ZnO and MgF2 on the same platform to achieve synergistic activity against both pathogens. Each surface is characterized, and the optimal conditions for the NP homogenous distribution on the surface are determined. The ZnO‐MgF2 surface significantly reduces the S. pneumoniae and S. aureus biofilm compared with the surfaces coated with either ZnO or MgF2, even though it contains smaller amounts of each NP type. Importantly, leaching assays show that the NPs remain anchored to the surface for at least 7 d. Finally, biocompatibility studies demonstrate that coating with low concentrations of ZnO‐MgF2 results in no toxicity toward primary human fibroblasts from the auditory canal. Taken together, these findings underscore the potential of using NP combinations such as the one presented here to efficiently inhibit bacterial colonization and growth on medical devices such as CIs.

show abstract

Intracochleäre Medikamentenapplikation in Verbindung mit Cochleaimplantaten

Plontke

Götze

Rahne

et al. 2016

HNO

View full text Add to dashboard Cite

Local drug application to the inner ear offers a number of advantages over systemic delivery. Local drug therapy currently encompasses extracochlear administration (intratympanic injection); intracochlear administration, particularly for gene and stem cell therapy; as well as various combinations with auditory neurosensory prostheses, either evaluated in preclinical or clinical studies, or off-label. To improve rehabilitation with cochlear implants (CI), one focus is the development of drug-releasing electrode carriers, e. g., to deliver glucocorticosteroids, antiapoptotic substances, or neurotrophines to the inner ear. By protecting neuronal structures from insertion trauma, reducing fibrosis in the inner ear, and by stimulating growth of neuronal structures in the direction of the electrodes, the performance of CIs should be improved. Controlled drug release after extracochlear or intracochlear application in conjunction with a CI can be achieved by, e.g., use of a biocompatible, resorbable controlled-release drug delivery systems. Two case reports are presented. In order to treat worsened speech discrimination and increased impedance, these CI-wearing patients successfully underwent intracochlear placement of a biocompatible, resorbable drug delivery system for controlled release of dexamethasone. The drug levels reached in inner ear fluids after different types of local drug application strategies can be calculated using computer models. The intracochlear drug concentrations calculated in this way were compared for different dexamethasone application strategies.

show abstract

Fine control of drug delivery for cochlear implant applications

Cited by 11 publications

References 6 publications

Cochlear Implant Strategies and Biomaterials from Past to Future

Cochlear Implant Strategies and Biomaterials from Past to Future

Two are Better than One: Combining ZnO and MgF₂ Nanoparticles Reduces Streptococcus pneumoniae and Staphylococcus aureus Biofilm Formation on Cochlear Implants

Intracochleäre Medikamentenapplikation in Verbindung mit Cochleaimplantaten

Contact Info

Product

Resources

About

Fine control of drug delivery for cochlear implant applications

Cited by 11 publications

References 6 publications

Cochlear Implant Strategies and Biomaterials from Past to Future

Cochlear Implant Strategies and Biomaterials from Past to Future

Two are Better than One: Combining ZnO and MgF2 Nanoparticles Reduces Streptococcus pneumoniae and Staphylococcus aureus Biofilm Formation on Cochlear Implants

Intracochleäre Medikamentenapplikation in Verbindung mit Cochleaimplantaten

Contact Info

Product

Resources

About

Two are Better than One: Combining ZnO and MgF₂ Nanoparticles Reduces Streptococcus pneumoniae and Staphylococcus aureus Biofilm Formation on Cochlear Implants